Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität, Munich, Germany.
Institute for Pathology, Faculty of Medicine, Ludwig-Maximilians-Universität, Munich, Germany.
J Allergy Clin Immunol. 2017 Oct;140(4):1112-1119. doi: 10.1016/j.jaci.2016.10.053. Epub 2017 Jan 21.
Myb-like, SWIRM, and MPN domains 1 (MYSM1) is a transcriptional regulator mediating histone deubiquitination. Its role in human immunity and hematopoiesis is poorly understood.
We sought to investigate the clinical, cellular, and molecular features in 2 siblings presenting with progressive bone marrow failure (BMF), immunodeficiency, and developmental aberrations.
We performed genome-wide homozygosity mapping, whole-exome and Sanger sequencing, immunophenotyping studies, and analysis of genotoxic stress responses. p38 activation, reactive oxygen species levels, rate of apoptosis and clonogenic survival, and growth in immune and nonimmune cells were assessed. The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monitored.
We report 2 patients with progressive BMF associated with myelodysplastic features, immunodeficiency affecting B cells and neutrophil granulocytes, and complex developmental aberrations, including mild skeletal anomalies, neurocognitive developmental delay, and cataracts. Whole-exome sequencing revealed a homozygous premature stop codon mutation in the gene encoding MYSM1. MYSM1-deficient cells are characterized by increased sensitivity to genotoxic stress associated with sustained induction of phosphorylated p38 protein, increased reactive oxygen species production, and decreased survival following UV light-induced DNA damage. Both patients were successfully treated with allogeneic HSCT with sustained reconstitution of hematopoietic defects.
Here we show that MYSM1 deficiency is associated with developmental aberrations, progressive BMF with myelodysplastic features, and increased susceptibility to genotoxic stress. HSCT represents a curative therapy for patients with MYSM1 deficiency.
Myb 样、SWIRM 和 MPN 结构域蛋白 1(MYSM1)是一种转录调节因子,介导组蛋白去泛素化。其在人类免疫和造血中的作用尚未完全了解。
我们旨在研究 2 名表现为进行性骨髓衰竭(BMF)、免疫缺陷和发育异常的同胞患者的临床、细胞和分子特征。
我们进行了全基因组纯合性作图、外显子组和 Sanger 测序、免疫表型研究以及遗传毒性应激反应分析。评估了 p38 激活、活性氧水平、凋亡率和集落形成细胞存活以及在免疫和非免疫细胞中的生长情况。监测了异基因造血干细胞移植(HSCT)的结果。
我们报告了 2 名患者,他们患有进行性 BMF,伴有骨髓增生异常特征,影响 B 细胞和中性粒细胞的免疫缺陷,以及复杂的发育异常,包括轻度骨骼异常、神经认知发育迟缓以及白内障。外显子组测序显示编码 MYSM1 的基因存在纯合提前终止密码子突变。MYSM1 缺陷细胞的特征是对遗传毒性应激的敏感性增加,与磷酸化 p38 蛋白的持续诱导、活性氧生成增加以及 UV 光诱导的 DNA 损伤后存活能力降低有关。两名患者均成功接受了异基因 HSCT 治疗,造血缺陷得到持续重建。
本研究表明,MYSM1 缺陷与发育异常、具有骨髓增生异常特征的进行性 BMF 以及对遗传毒性应激的易感性增加有关。HSCT 是治疗 MYSM1 缺陷患者的有效方法。